small
interf
rna
sirna
huge
potenti
treatment
prevent
variou
lung
diseas
rna
molecul
success
enter
target
cell
could
inhibit
express
specif
gene
sequenc
rna
interfer
rnai
mechan
gener
therapeut
effect
biggest
obstacl
translat
sirna
therapi
laboratori
clinic
deliveri
ideal
deliveri
agent
protect
sirna
enzymat
degrad
facilit
cellular
uptak
promot
endosom
escap
insid
cell
neglig
toxic
lung
target
could
achiev
system
deliveri
pulmonari
deliveri
latter
rout
administr
could
potenti
enhanc
sirna
retent
lung
reduc
system
toxic
effect
howev
presenc
mucu
mucociliari
clearanc
action
high
degre
branch
airway
present
major
barrier
target
pulmonari
deliveri
deliveri
system
need
design
care
order
maxim
sirna
deposit
diseas
area
airway
pulmonari
sirna
therapi
studi
vivo
sirna
deliv
either
intratrach
intranas
limit
work
done
formul
sirna
inhal
believ
direct
futur
develop
review
focus
latest
develop
pulmonari
deliveri
sirna
treatment
variou
lung
diseas
rna
interfer
rnai
huge
therapeut
potenti
treat
mani
diseas
silenc
express
target
gene
posttranscript
manner
mechan
rnai
extens
review
literatur
brief
rnai
achiev
artifici
three
major
way
introduc
long
doubl
strand
rna
dsrna
cleav
small
interf
rna
sirna
enzym
dicer
cytoplasm
lead
degrad
target
mrna
ii
introduc
plasmid
dna
encod
short
hairpin
rna
shrna
process
dicer
sirna
iii
introduc
small
interf
rna
sirna
directli
initi
mrna
degrad
process
last
two
decad
scientist
investig
use
nucleic
acid
includ
dna
antisens
oligonucleotid
therapeut
agent
biggest
hurdl
encount
deliveri
problem
appli
rnai
therapi
neg
charg
hydrophil
macromolecul
highli
suscept
nucleas
degrad
nucleic
acid
incap
cross
biolog
membran
reach
site
action
deliveri
vector
therefor
requir
protect
therapeut
nucleic
acid
enzymat
degrad
facilit
cellular
uptak
releas
nucleic
acid
site
action
insid
cell
amongst
type
nucleic
acid
involv
rnai
sirna
popular
candid
studi
rnai
therapi
introduct
long
dsrna
typic
consist
base
pair
known
induc
interferon
ifn
respons
mammalian
cell
render
unsuit
rnai
therapi
wherea
sirna
typic
consist
base
pair
avoid
inf
respons
deliveri
perspect
sirna
advantag
plasmid
dna
encod
shrna
order
dna
properli
express
must
enter
nucleu
transcript
take
place
nuclear
entri
extrem
ineffici
process
inde
consid
one
biggest
barrier
success
gene
therapi
hand
sirna
target
rnainduc
silenc
complex
risc
locat
cytoplasm
although
shrna
higher
gene
silenc
potenc
sirna
rel
eas
deliveri
make
sirna
better
candid
rnai
therapi
fact
deliveri
sirna
success
rnai
molecul
first
human
clinic
trial
rnai
therapi
initi
treatment
agerel
macular
degener
amd
sirna
target
vegfreceptor
deliv
intravitr
sinc
number
clinic
trial
sirna
therapi
conduct
differ
condit
includ
solid
tumor
cancer
respiratori
syncyti
viru
rsv
infect
tabl
show
summari
clinic
trial
sirna
therapi
rnai
potenti
use
treat
prevent
diseas
affect
airway
lung
cancer
variou
type
respiratori
infecti
diseas
airway
inflammatori
diseas
cystic
fibrosi
sirna
deliveri
lung
could
achiev
either
local
deliveri
system
deliveri
former
rout
offer
sever
import
benefit
latter
lower
dose
sirna
requir
reduct
undesir
system
side
effect
improv
sirna
stabil
due
lower
nucleas
activ
airway
serum
furthermor
lung
could
potenti
serv
interest
site
deliv
sirna
system
effect
due
high
vascular
larg
surfac
area
ultra
thin
epithelium
alveoli
factor
allow
effici
rapid
sirna
absorpt
process
pulmonari
sirna
deliveri
summar
fig
sever
way
administ
sirna
local
lung
inhal
common
easiest
method
pulmonari
drug
deliveri
could
appli
sirna
deliveri
sirna
inhal
formul
liquid
aerosol
dri
powder
aerosol
intranas
rout
anoth
common
way
deliv
sirna
airway
due
eas
administr
intranas
sirna
prepar
easili
administ
nasal
caviti
nasal
suspens
intratrach
rout
administr
also
employ
deliv
sirna
lung
howev
method
administr
rel
invas
nonphysiolog
gener
consid
use
anim
studi
rather
clinic
applic
regardless
administr
rout
import
maintain
sirna
stabil
biolog
activ
manufactur
deliveri
similar
dna
deliveri
viral
nonvir
vector
employ
deliv
sirna
virus
extrem
effici
nucleic
acid
deliveri
vector
evolv
transfer
genet
materi
host
cell
enabl
virus
deliv
nucleic
acid
therapeut
use
virus
must
first
genet
engin
remov
virul
main
advantag
use
viral
vector
high
transduct
effici
compar
transfect
nonvir
method
virus
adenoviru
adenoassoci
viru
lentiviru
investig
deliv
sirna
lung
cell
despit
high
nucleic
acid
transfer
effici
safeti
concern
regard
use
viral
vector
lesson
learnt
dna
deliveri
high
risk
associ
util
viral
vector
immun
respons
virus
major
challeng
viral
deliveri
limit
effect
therapi
repeat
administr
sever
case
immun
respons
even
lead
organ
failur
consequ
could
fatal
furthermor
sever
type
viru
may
insert
genom
randomli
host
chromosom
disturb
gene
function
result
insert
mutagenesi
infam
gelsing
case
year
old
volunt
gelsing
die
gene
therapi
trial
use
adenoviru
french
xscid
case
one
third
children
develop
leukemia
gene
therapi
trial
use
retroviru
hard
imagin
chanc
use
viral
vector
type
human
nucleic
acid
therapi
get
approv
fda
extrem
slim
viral
vector
excel
agent
deliv
sirna
proofofconcept
studi
appear
lack
real
clinic
applic
safeti
issu
altern
way
deliv
sirna
nonvir
method
includ
method
involv
use
virus
therapeut
sirna
either
administ
directli
site
action
deliv
nonvir
vector
commonli
use
nonvir
vector
sirna
deliveri
includ
lipid
polym
peptid
thoma
et
al
review
nonvir
sirna
deliveri
lung
review
publish
focus
deliveri
sirna
treatment
three
differ
lung
viru
infect
influenza
respiratori
syncyti
viru
infect
sever
acut
respiratori
syndrom
sar
field
sirna
deliveri
rapidli
expand
sinc
good
number
vivo
studi
carri
past
year
investig
local
deliveri
sirna
variou
lung
diseas
includ
lung
cancer
mycobacteria
infect
pulmonari
fibrosi
respiratori
alphaherpesviru
infect
endogen
gene
target
lung
review
present
latest
develop
sirna
therapi
treatment
variou
lung
diseas
discuss
challeng
pulmonari
drug
administr
barrier
sirna
deliveri
lung
includ
extracellular
intracellular
barrier
focu
nonvir
deliveri
method
find
recent
clinic
studi
pulmonari
sirna
therapi
also
discuss
pulmonari
deliveri
therapeut
macromolecul
protein
peptid
investig
thirti
year
challeng
sirna
deliveri
via
pulmonari
rout
similar
deliveri
macromolecul
order
develop
effici
sirna
pulmonari
deliveri
system
import
understand
anatom
physiolog
properti
respiratori
tract
first
place
respiratori
tract
divid
two
region
conduct
region
consist
nasal
caviti
pharynx
trachea
bronchi
bronchiol
ii
respiratori
region
consist
respiratori
bronchiol
alveoli
conduct
region
respons
air
conduct
respiratori
region
gaseou
exchang
take
place
promin
featur
respiratori
tract
high
degre
branch
accord
wiebel
model
lung
gener
total
highli
branch
structur
compris
airway
vari
length
diamet
present
earli
barrier
target
pulmonari
deliveri
mani
lung
diseas
affect
lower
region
lung
therapeut
agent
reach
diseas
area
must
follow
airstream
around
bend
along
branch
airway
deep
lung
area
size
particl
import
factor
determin
site
deposit
illustr
fig
pulmonari
deliveri
size
particl
express
term
aerodynam
diamet
larg
particl
aerodynam
diamet
carri
high
momentum
like
impact
airway
wall
bifurc
instead
follow
chang
airstream
therefor
usual
deposit
higher
airway
back
throat
pharynx
small
particl
aerodynam
diamet
movement
determin
brownian
motion
mostli
exhal
normal
tidal
breath
paus
enhanc
deposit
probabl
latter
proport
squar
root
time
optim
particl
size
effici
deposit
lower
respiratori
tract
found
particl
size
decreas
toward
nanoscal
deposit
lung
increas
due
increas
diffusion
mobil
nanoparticl
less
nm
appear
settl
effect
alveolar
region
fraction
deposit
around
howev
ultrafin
particl
usual
enter
lung
larger
agglomer
broken
rel
easili
smaller
particl
deposit
variou
elimin
pathway
nanoparticl
exist
lung
includ
cough
dissolut
mucociliarli
escal
transloc
airway
site
phagocytosi
macrophag
neuron
uptak
establish
quantit
relationship
pathway
littl
known
exactli
sirna
clear
lung
major
barrier
pulmonari
deliveri
includ
mucociliari
clearanc
action
ciliat
epitheli
cell
presenc
mucu
alveolar
fluid
macrophag
along
differ
part
airway
particl
deposit
ciliat
cell
rapidli
remov
mucociliari
clearanc
eventu
cough
swallow
mucu
line
respiratori
epithelium
nasal
caviti
termin
bronchiol
major
compon
mucu
mucin
glycosyl
protein
mucu
constitut
physic
barrier
increas
viscos
moist
surfac
lung
epitheli
cell
therebi
reduc
drug
penetr
diffus
rate
alveolar
fluid
found
surfac
alveoli
epithelium
thin
layer
pulmonari
surfact
compris
phospholipid
surfact
protein
report
pulmonari
surfact
sever
imped
transfect
effici
lipidbas
nucleic
acid
deliveri
system
polymerbas
system
alveolar
macrophag
locat
alveoli
rapidli
engulf
foreign
particl
phagocytosi
defens
mechan
sirna
taken
macrophag
subsequ
degrad
insid
cell
diseas
state
physiolog
condit
airway
might
alter
pose
huge
impact
effici
pulmonari
deliveri
system
infect
inflamm
increas
mucu
secret
mucociliari
clearanc
impair
thick
viscos
composit
mucu
layer
depend
patholog
condit
vari
individu
import
factor
consid
develop
pulmonari
deliveri
system
differ
therapeut
applic
overcom
anatom
physiolog
barrier
lung
sever
deliveri
strategi
incorpor
besid
use
particl
small
aerodynam
diamet
suitabl
deposit
lower
airway
report
use
larg
porou
particl
effect
avoid
phagocytosi
alveolar
macrophag
prolong
retent
time
lung
porou
particl
geometr
diamet
usual
smaller
aerodynam
diamet
within
ideal
aerodynam
size
rang
effect
lung
deposit
actual
geometr
size
larg
remov
macrophag
overcom
mucu
barrier
use
mucolyt
agent
nacystelyn
break
three
dimension
gel
network
mucu
use
mucu
inhibitor
glycopyrrol
inhibit
mucu
secret
could
consid
howev
clinic
benefit
limit
inhal
mannitol
clinic
proven
increas
mucu
clearanc
patient
cystic
fibrosi
bronchietasi
improv
hydrat
surfac
properti
sputum
reduc
mucu
barrier
mannitol
inhal
prior
deliveri
sirna
may
thu
benefici
use
ultrasound
magnet
field
also
report
direct
control
site
deposit
nucleic
acid
deliveri
system
airway
sirna
reach
surfac
target
cell
respiratori
tract
assum
success
get
away
extracellular
barrier
still
cross
cellular
membran
gain
access
cytoplasm
risc
final
target
sirna
locat
sirna
neg
charg
hydrophil
macromolecul
molecular
weight
around
kda
base
physicochem
properti
sirna
abl
cross
biolog
membran
therefor
one
main
function
deliveri
vector
facilit
cellular
uptak
sirna
endocytosi
major
cellular
uptak
pathway
known
involv
nonvir
nucleic
acid
deliveri
effici
endocytosi
occur
particl
nm
size
particl
within
size
rang
could
also
avoid
macrophag
uptak
therebi
delay
lung
clearanc
particl
enter
respiratori
tract
larg
aggreg
must
redispers
deaggreg
appropri
size
endocytosi
could
take
place
yet
sever
differ
type
endocyt
pathway
turn
affect
set
barrier
macromolecul
may
encount
eventu
fate
molecul
could
differ
clathrinmedi
endocytosi
major
bestcharacter
endocyt
pathway
occur
constitut
mammalian
cell
particl
taken
cell
pathway
enclos
clathrinco
vesicl
transport
earli
endosom
fuse
form
late
endosom
subsequ
lysosom
process
ph
insid
vesicl
drop
gradual
low
ph
lysosom
degrad
enzym
includ
nucleas
present
therefor
therapeut
sirna
must
abl
exit
endosomeslysosom
cytoplasm
degrad
nucleas
fig
sever
strategi
employ
promot
endosom
escap
sirna
polym
polyethylenimin
pei
abil
trigger
endosom
releas
proton
spong
hypothesi
suggest
due
high
buffer
capac
pei
wide
rang
ph
polym
becom
proton
ph
drop
insid
endosom
lead
influx
chlorid
ion
proton
subsequ
water
endosom
eventu
high
osmot
pressur
develop
caus
endosom
burst
open
releas
content
cytoplasm
howev
cellular
effect
endosom
burst
properli
discuss
evalu
pei
also
known
associ
toxic
problem
anoth
strategi
incorpor
ph
sensit
fusogen
peptid
deliveri
system
fusogen
peptid
gala
kala
etc
employ
sirna
deliveri
vitro
vivo
peptid
abil
undergo
phdepend
conform
chang
low
ph
adopt
membranedisrupt
conform
destabil
endosom
membran
therebi
releas
content
endosom
cytoplasm
apart
clathrinmedi
endocytosi
caveolaemedi
endocytosi
anoth
mechan
involv
uptak
nucleic
acid
deliveri
system
intern
deliveri
system
enclos
caveolinco
vesicl
call
caveosom
nonacid
nucleas
degrad
enzym
absenc
caveosom
deliveri
system
directli
transport
golgi
andor
endoplasm
reticulum
therebi
avoid
lysosom
degrad
sinc
caveolin
abundantli
express
mani
cell
type
includ
lung
tissu
import
rout
cell
intern
pulmonari
deliveri
perhap
effici
rout
compar
clathrinmedi
endocytosi
especi
deliveri
system
lack
abil
escap
acid
endosom
compart
entrap
sirna
insid
endosomeslysosom
lead
degrad
nucleic
acid
may
also
trigger
activ
innat
immun
evid
suggest
synthet
sirna
recogn
tolllik
receptor
tlr
insid
endosom
compart
therebi
stimul
innat
immun
respons
modif
sirna
could
circumv
problem
approach
may
advers
affect
gene
silenc
effici
altern
earli
escap
complet
bypass
endosom
intracellular
deliveri
process
could
perhap
avoid
immunostimulatori
activ
sirna
moscho
et
al
report
tatconjug
sirna
administ
lung
mous
immun
respons
observ
howev
penetratinconjug
sirna
administ
way
innat
immun
respons
observ
possibl
activ
tlr
sinc
sirna
tat
penetratin
alon
induc
innat
immun
respons
differ
fate
tatconjug
penetratinconjug
sirna
system
could
explain
differ
cellular
uptak
mechan
studi
demonstr
import
cellular
uptak
pathway
intracellular
traffick
establish
safeti
profil
well
effici
sirna
deliveri
lastli
phagocytosi
anoth
cellular
uptak
mechan
occur
respiratori
tract
sinc
rout
uptak
perform
special
cell
alveolar
macrophag
expect
play
import
role
sirna
deliveri
unless
therapeut
sirna
aim
target
alveolar
macrophag
eg
treatment
mycobacterium
infect
pathway
total
avoid
molecul
taken
pathway
eventu
degrad
phagolysosom
cell
direct
pulmonari
deliveri
human
achiev
inhal
aerosol
gener
either
inhal
nebul
new
therapeut
agent
use
human
clinic
trial
must
demonstr
preclin
efficaci
suitabl
anim
model
good
translat
human
except
therapeut
sirna
addit
inhal
intratrach
intranas
rout
often
use
deliv
therapeut
agent
includ
sirna
lung
anim
rel
simpl
setup
summari
vivo
studi
nonvir
sirna
deliveri
lung
provid
tabl
rout
administr
commonli
use
studi
illustr
fig
intratrach
intranas
method
may
practic
clinic
set
intratrach
rout
invas
method
deliveri
appropri
human
use
success
deliv
sirna
via
intranas
rout
rodent
oblig
nose
breather
extrapol
human
use
differ
lung
anatomi
therefor
import
take
consider
rout
administr
anim
studi
assess
deliveri
therapeut
efficaci
formul
lung
deliveri
inhal
popular
noninvas
way
deliv
therapeut
agent
lung
three
main
type
inhal
devic
current
avail
deliv
drug
lung
inhal
includ
meter
dose
inhal
mdi
dri
powder
inhal
dpi
nebul
appropri
modif
optim
devic
could
appli
pulmonari
deliveri
sirna
date
mdi
commonli
use
inhal
pressur
dosag
form
therapeut
agent
either
dissolv
suspend
propel
chlorofluorocarbon
cfc
hydrofluoroalkan
hfa
propel
serv
provid
drive
pressur
aerosol
drug
inhal
respiratori
tract
howev
cfc
hfa
known
environment
impact
compat
formul
propel
anoth
potenti
problem
lung
deposit
gener
poor
mdi
may
best
direct
develop
inhal
sirna
dpi
aerosol
system
drug
inhal
cloud
dri
particl
use
dpi
appear
promis
way
deliv
sirna
lung
demonstr
success
vivo
deliveri
therapeut
macromolecul
includ
insulin
parathyroid
hormon
low
molecular
weight
heparin
formul
challeng
potenti
solut
deliveri
macromolecul
protein
powder
aerosol
review
formul
biolog
macromolecul
powder
aerosol
deliveri
challeng
requir
flowabl
dispers
powder
also
biochem
stabil
macromolecul
satisfi
latter
requir
protein
usual
formul
amorph
glass
howev
physic
unstabl
tend
crystal
interparticul
bond
format
loss
powder
dispersibl
addit
biochem
stabil
requir
limit
manufactur
process
use
protein
powder
product
similar
issu
encount
sirna
nevertheless
possibl
way
tackl
challeng
address
inhal
dri
powder
form
insulin
exubera
market
pfizer
approv
europ
us
treatment
diabet
although
product
withdrawn
market
subsequ
year
pfizer
stress
disappoint
sale
major
reason
withdraw
rather
safeti
efficaci
issu
safeti
profil
inhal
insulin
inde
reassur
efficaci
inferior
convent
inject
formul
second
inhal
insulin
product
dri
powder
form
afresa
current
await
fda
approv
encourag
develop
dri
powder
form
macromolecul
inhal
differ
design
dpi
devic
deliveri
perform
may
vari
key
advantag
dpi
improv
stabil
steril
biomolecul
liquid
aerosol
propellantfre
formul
inhal
dri
powder
form
protein
peptid
commonli
produc
spraydri
techniqu
could
appli
sirna
size
spraydri
product
must
care
optim
effici
deliveri
desir
site
along
respiratori
tract
suitabl
deliveri
agent
formul
requir
protect
nucleic
acid
degrad
caus
shear
forc
rais
temperatur
dri
process
major
drawback
dpi
drug
deposit
could
depend
patient
inspir
flow
rate
therefor
suitabl
dpi
devic
must
care
design
minim
variat
addit
problem
associ
deaggreg
dri
powder
must
overcom
nebul
use
gener
liquid
aerosol
util
deliv
larg
volum
drug
solut
suspens
inhal
frequent
use
drug
unsuit
formul
mdi
dpi
could
consid
sirna
deliveri
process
nebul
high
shear
stress
exert
sirna
may
lead
degrad
nucleic
acid
particular
problem
gener
aerosol
droplet
recycl
back
reservoir
shear
stress
could
repeatedli
exert
nucleic
acid
addit
biomolecul
tend
less
stabl
liquid
form
dri
powder
form
stabil
prime
concern
deliv
sirna
nebul
suitabl
deliveri
vector
therefor
requir
protect
sirna
physic
chemic
degrad
although
inhal
common
way
deliv
drug
lung
best
knowledg
none
vivo
studi
sirna
therapi
intend
inhal
vivo
studi
use
either
intratrach
intranas
rout
deliveri
lung
could
due
difficulti
formul
inhal
sirna
especi
maintain
stabil
biolog
activ
sirna
manufactur
deliveri
process
recent
jensen
et
al
report
product
sirna
load
poli
llactidecoglycolid
plga
nanoparticl
spraydri
integr
biolog
activ
sirna
success
preserv
dri
process
physicochem
properti
particl
suitabl
inhal
interest
evalu
vivo
perform
formul
intratrach
rout
commonli
use
lung
deliveri
anim
studi
kind
drug
howev
clinic
applic
limit
method
initi
describ
exposur
techniqu
evalu
respiratori
tract
toxic
airborn
materi
later
adapt
assess
pulmonari
drug
deliveri
mainli
rodent
intratrach
rout
nonphysiolog
extrem
uncomfort
deliveri
techniqu
therefor
employ
routin
rout
drug
administr
human
use
tradit
method
requir
surgic
procedur
includ
tracheotomi
anim
anesthet
usual
sodium
pentobarbit
combin
xylazin
ketamin
anim
place
surgic
board
trachea
expos
endotrach
tube
needl
insert
incis
made
tracheal
cartilagin
ring
project
tip
defin
posit
tracheal
bifurc
drug
solut
suspens
instil
airway
tube
use
microsyring
fig
rel
noninvas
way
achiev
pulmonari
deliveri
via
intratrach
rout
describ
bivasbenita
et
al
surgic
procedur
requir
anim
still
need
anesthet
still
anesthesia
tongu
anim
gentli
pull
microspray
similar
devic
care
insert
endotrach
deliv
aerosol
lung
altern
anim
intub
mouth
trachea
use
cathet
needl
drug
instil
solut
suspens
form
procedur
sinc
deliveri
made
mouth
also
refer
orotrach
rout
correct
insert
trachea
may
straightforward
fig
mani
vivo
studi
employ
intratrach
rout
deliv
sirna
lung
main
advantag
intratrach
deliveri
ensur
high
deliveri
effici
minim
drug
lost
make
excel
deliveri
method
proofofconcept
studi
local
deliveri
lung
desir
success
intratrach
sirna
deliveri
lung
mous
first
report
perl
et
al
group
demonstr
use
mice
overexpress
gfp
intratrach
instil
sirna
target
gfp
display
reduc
fluoresc
intens
lung
liver
spleen
investig
gene
knockdown
effici
sirna
target
fa
deliv
way
mrna
express
fa
lung
tissu
found
significantli
reduc
work
also
show
sirna
induc
lung
inflamm
assess
lung
tissu
tumor
necrosi
interleukin
il
level
interestingli
deliveri
vector
requir
achiev
vivo
sirna
transfect
rosastaraco
et
al
also
report
success
deliveri
nake
sirna
intratrach
rout
aerosol
sirna
target
administ
intratrach
mous
infect
tuberculosi
express
lung
suppress
mrna
protein
level
sinc
express
affect
format
lung
granuloma
known
associ
mycobacterium
tuberculosi
infect
local
deliveri
sirna
may
exploit
novel
therapi
treatment
tuberculosi
observ
success
vivo
gene
knockdown
mediat
nake
sirna
discuss
later
studi
perform
compar
sirna
mediat
silenc
without
deliveri
vector
via
intratrach
rout
moscho
et
al
report
nake
sirna
fail
mediat
gene
silenc
vitro
mous
fibroblast
cell
line
wherea
conjug
sirna
cell
penetr
peptid
tat
penetratin
lipid
carrier
cholesterol
result
gene
silenc
effect
mrna
level
surprisingli
proceed
vivo
studi
found
nake
sirna
manag
produc
gene
knockdown
mrna
level
neither
tat
penetratin
improv
transfect
effici
compar
nake
sirna
use
cell
penetr
peptid
even
found
trigger
inflammatori
respons
lung
tissu
recent
studi
gutbier
et
al
demonstr
epitheli
ecadherin
reduc
moder
mous
lung
tissu
follow
intratrach
deliveri
nake
targetspecif
sirna
signific
reduct
endotheli
vecadherin
lamin
observ
use
lipidbas
deliveri
vector
dphypedspepeg
found
evok
inflammatori
respons
lung
despit
success
intratrach
rout
sirna
deliveri
anim
model
must
note
intratrach
rout
artifici
way
deliv
drug
lung
drug
deposit
rout
tend
less
uniform
compar
inhal
sinc
intratrach
fig
schemat
illustr
rout
sirna
administr
lung
use
vivo
studi
intratrach
routetrachea
anim
expos
surgic
tube
insert
incis
made
tracheal
ring
solutionsuspens
instil
tube
use
microsyring
b
orotrach
routeth
anim
intub
mouth
trachea
solutionsuspens
instil
oral
caviti
avoid
need
surgeri
c
intranas
routea
micropipett
cathet
contain
solutionsuspens
insert
gentli
nari
anim
solutionsuspens
slowli
instil
nasal
caviti
rout
avoid
oropharynx
deposit
reduc
drug
loss
addit
effect
aerosol
size
critic
factor
affect
human
lung
deposit
focu
investig
studi
therefor
difficult
reli
rout
administr
accur
evalu
vivo
deliveri
effici
particular
formul
intranas
rout
anoth
popular
way
deliv
sirna
lung
anim
studi
partli
easi
experiment
setup
anim
usual
lightli
deepli
anesthet
sirna
formul
instil
dropwis
nari
breath
fig
number
studi
show
success
sirna
deliveri
lung
vivo
rout
zhang
et
al
first
demonstr
lungspecif
sirna
deliveri
could
achiev
mous
intranas
administr
without
need
deliveri
vector
nake
sirna
target
heme
effect
suppress
express
gene
injur
lung
model
mous
soon
deliveri
nake
sirna
via
intranas
rout
shown
success
inhibit
lung
viral
infect
mous
rhesu
macaqu
sinc
anatomi
physiolog
lung
mous
human
differ
success
see
intranas
sirna
deliveri
lung
could
easili
translat
human
use
mice
oblig
nasal
breather
surpris
see
high
proport
sirna
deliv
nose
deposit
lung
addit
use
anesthet
anim
studi
may
impair
mucociliari
action
therebi
overestim
transfect
effici
formul
order
evalu
feasibl
lung
deliveri
via
nasal
rout
human
heyder
et
al
perform
experi
healthi
adult
volunt
ask
inhal
monodispers
particl
nose
fix
flow
volum
found
particl
deposit
bronchial
airway
nose
breath
major
particl
deposit
nose
instead
reason
intranas
rout
perfect
deliv
sirna
nasopharynx
area
fact
one
human
clinic
trial
current
phase
ii
stage
use
rout
deliv
sirna
treatment
human
rsv
infect
rsv
upper
respiratori
diseas
sirna
develop
alnylam
pharmaceut
design
inhibit
replic
rsv
interrupt
synthesi
viral
nucleocapsid
protein
sinc
rsv
replic
almost
exclus
singl
outermost
layer
cell
respiratori
epithelium
includ
line
nasal
passag
trachea
local
deliveri
nasopharynx
could
potenti
treat
infect
deliv
without
deliveri
vector
nasal
spray
target
upper
respiratori
tract
instead
deep
lung
area
author
also
point
nasal
spray
would
expect
reach
lower
respiratori
tract
develop
aerosol
drug
target
lower
respiratori
tract
desir
futur
trial
treatment
natur
infect
patient
furthermor
intranas
rout
develop
long
time
administ
macromolecul
protein
peptid
system
deliveri
rel
larg
absorpt
surfac
area
nasal
caviti
high
vascular
nasal
mucosa
facilit
rapid
absorpt
intranas
rout
definit
rout
explor
system
deliveri
sirna
deliveri
vector
often
requir
facilit
cellular
deliveri
sirna
highli
charg
hydrophil
natur
macromolecul
make
unabl
cross
biolog
membran
reach
target
site
due
safeti
concern
viralvector
mani
sirna
deliveri
studi
focu
develop
nonvir
vector
ideal
sirna
deliveri
vector
consist
follow
criteria
condens
sirna
nanos
particl
ii
protect
sirna
enzymat
degrad
iii
facilit
cellular
uptak
iv
promot
endosom
escap
v
releas
sirna
cytoplasm
risc
locat
vi
neglig
toxic
addit
optim
deliveri
achiev
without
compromis
gene
silenc
activ
specif
sirna
commonli
use
nonvir
sirna
deliveri
vector
includ
lipid
polym
peptid
interestingli
nake
sirna
also
found
success
produc
gene
silenc
effect
vivo
vector
illustr
fig
pulmonari
deliveri
use
system
discuss
detail
term
nake
sirna
unformul
sirna
refer
deliveri
sirna
without
use
deliveri
agent
includ
deliveri
unmodifi
sirna
modifi
sirna
formul
salin
simpl
excipi
dextros
sinc
unmodifi
sirna
suscept
nucleas
degrad
chemic
modifi
sirna
introduc
initi
address
issu
increas
nucleas
resist
sirna
also
chemic
modifi
improv
potenc
increas
specif
reduc
immun
respons
reduc
offtarget
effect
subject
sirna
modif
thoroughli
review
watt
et
al
major
consider
sirna
modif
ensur
gene
silenc
effici
sirna
advers
affect
system
deliveri
nake
sirna
gener
fail
produc
signific
gene
silenc
effect
surprisingli
success
deliv
nake
unmodifi
sirna
local
includ
lung
tabl
studi
alreadi
discuss
section
usual
nake
sirna
administr
either
intranas
intratrach
mous
sirna
target
endogen
viral
gene
case
use
deliveri
vector
lipid
peptid
show
margin
improv
gene
silenc
effici
lung
compar
nake
sirna
observ
truli
intrigu
question
nake
sirna
cross
biolog
membran
order
achiev
posttranscript
gene
silenc
remain
answer
although
reduc
nucleas
activ
lung
may
provid
part
explan
bitko
et
al
report
nake
unmodifi
sirna
abl
prevent
respiratori
viral
infect
sirnamedi
gene
knockdown
nake
sirna
administr
intranas
mous
author
suggest
lung
tissu
perhap
recept
exchang
molecul
natur
infect
explan
yet
confirm
nevertheless
deliveri
nake
sirna
extend
clinic
trial
mention
previou
section
modifi
form
sirna
administr
intranas
nasal
spray
without
use
deliveri
vector
initi
data
confirm
effici
reduc
rsv
infect
regardless
mysteri
nake
sirna
cross
cell
membran
gain
access
cytoplasm
remain
intact
perform
biolog
action
perform
nake
sirna
far
anim
model
human
studi
promis
major
advantag
use
nake
sirna
simplic
without
need
concern
toxic
inflammatori
respons
associ
certain
deliveri
vector
howev
must
stress
order
make
formul
applic
deep
lung
deliveri
human
aerosol
inhal
still
administr
rout
choic
particul
carrier
requir
deliv
sirna
dri
powder
form
deliveri
agent
need
protect
sirna
shear
forc
produc
nebul
process
suspens
form
use
deliveri
agent
could
also
enhanc
specif
cell
target
improv
pharmacokinet
facilit
cellular
uptak
studi
indic
use
optim
deliveri
vector
could
significantli
improv
lung
deliveri
effici
anim
model
includ
nonhuman
primat
compar
nake
sirna
therefor
develop
effect
vector
pulmonari
sirna
deliveri
still
focu
research
field
lipidbas
deliveri
system
commonli
use
deliv
sirna
vitro
vivo
typic
cation
lipid
liposom
use
form
complex
neg
charg
sirna
spontan
electrostat
interact
complex
refer
lipoplex
mani
commerci
sirna
transfect
agent
lipidsbas
system
also
employ
vivo
pulmonari
deliveri
eg
transittko
dharmfect
major
challeng
use
lipidbas
deliveri
vector
clinic
toxic
nonspecif
activ
inflammatori
cytokin
interferon
respons
lipoplex
aerosol
special
attent
must
given
stabil
may
undergo
physic
chemic
chang
may
result
immatur
releas
henc
degrad
sirna
order
maxim
stabil
deliveri
effici
minim
toxic
side
effect
crucial
optim
lipid
composit
lipid
sirna
ratio
lipoplex
prepar
method
lipoplex
easi
prepar
gener
good
transfect
effici
due
effici
interact
neg
charg
cell
membran
howev
also
present
disadvantag
poor
stabil
poor
reproduc
moreov
cation
lipid
liposom
gener
toxic
neutral
counterpart
studi
perform
dokka
et
al
show
pulmonari
administr
cation
liposom
lipofectamin
dotap
elicit
doserespons
toxic
pulmonari
inflamm
mice
effect
pronounc
multival
lipofectamin
monoval
dotap
addit
found
neutral
anion
liposom
exhibit
lung
toxic
circumv
problem
associ
posit
surfac
charg
hydrophil
polym
polyethylen
glycol
peg
employ
shield
surfac
charg
cation
lipid
liposom
attempt
reduc
inflammatori
respons
peg
coval
link
phospholipid
use
mani
year
prolong
circul
bloodstream
reduc
opson
subsequ
cell
captur
mononuclear
phagocyt
system
cation
lipid
genzym
lipid
previous
investig
plasmid
dna
deliveri
lung
treatment
cystic
fibrosi
human
clinic
trial
consist
dope
dmpepeg
molar
ratio
complex
dna
result
lipoplex
aerosol
administr
patient
jet
nebul
patient
receiv
treatment
chlorid
abnorm
found
significantli
improv
bacteri
adher
lung
reduc
promis
result
led
investig
lipidbas
system
sirna
deliveri
griesenbach
et
al
assess
vivo
effici
deliv
sirna
lung
mice
via
intranas
rout
sirna
target
found
local
alveolar
macrophag
mrna
reduc
approxim
signific
chang
protein
express
perhap
use
nebul
could
consid
investig
lipid
system
apart
pegyl
anoth
way
avoid
toxic
inflammatori
respons
lipidbas
system
use
neutral
lipid
base
system
although
neutral
system
favor
safeti
profil
lack
interact
neg
charg
sirna
limit
use
deliveri
vector
sever
method
overcom
issu
one
strategi
link
sirna
lipid
togeth
direct
conjug
instead
electrostat
interact
demonstr
chemic
conjug
sirna
cholesterol
facilit
sirna
uptak
vivo
system
administr
moscho
et
al
appli
strategi
pulmonari
deliveri
sirna
cholesterolsirna
conjug
deliv
mice
intratrach
administr
durat
gene
knockdown
effect
extend
cholesterolconjug
system
mrna
level
compar
nake
sirna
howev
magnitud
knockdown
improv
importantli
cholesterolsirna
conjug
elicit
inflamm
mice
tissu
altern
strategi
improv
safeti
profil
lipidbas
system
encapsul
sirna
insid
neutral
lipid
particl
sempl
et
al
introduc
util
ph
sensit
ioniz
aminolipid
facilit
effici
encapsul
antisens
oligonucleotid
lipid
vesicl
import
characterist
lipid
exhibit
posit
charg
acid
ph
neutral
charg
physiolog
ph
therebi
provid
mean
lipid
effici
interact
nucleic
acid
lipid
vesicl
render
neutral
physiolog
ph
sempl
et
al
develop
techniqu
produc
stabl
nucleic
acid
lipid
particl
snalp
uniform
size
high
sirna
encapsul
deliveri
effici
two
import
paramet
underli
lipid
design
snalpmedi
deliveri
pka
ioniz
cation
lipid
determin
surfac
charg
lipid
particl
differ
ph
condit
ii
abil
proton
induc
nonbilay
phase
structur
mix
anion
lipid
properti
lipid
determin
membran
destabil
capac
endosomolyt
potenti
lipid
particl
snalp
demonstr
effici
vivo
gene
silenc
administ
intraven
nonhuman
primat
system
could
exploit
pulmonari
deliveri
recent
new
class
lipidlik
deliveri
molecul
term
lipidoid
develop
sirna
deliveri
combinatori
approach
employ
allow
rapid
synthesi
larg
librari
structur
divers
lipidoid
librari
screen
abil
deliv
sirna
vitro
vivo
lead
candid
vivo
sirna
mediat
gene
knockdown
identifi
system
test
abil
inhibit
rsv
replic
lung
intranas
administr
mous
model
rsv
infect
nake
sirna
provid
one
log
reduct
viral
plaqu
lung
tissu
wherea
lipoidoid
system
dose
sirna
provid
greater
two
log
reduct
viral
plaqu
method
provid
possibl
rapid
design
new
lipidbas
materi
pulmonari
sirna
deliveri
one
attract
properti
polymerbas
deliveri
vector
versatil
natur
allow
physicochem
characterist
modifi
rel
easili
fit
purpos
addit
suggest
polym
gener
evok
strong
immun
respons
liposom
gener
polymerbas
vector
divid
two
categori
polyc
polymer
nanoparticl
synthet
polyc
polyethylenimin
pei
polyamidoamin
pamam
dendrim
natur
polyc
chitosan
use
deliv
dna
long
time
polym
high
cation
charg
densiti
form
polyplex
spontan
neg
charg
nucleic
acid
electrostat
interact
size
polyplex
affect
molecular
weight
polym
charg
ratio
ph
ionic
strength
medium
net
posit
charg
requir
maintain
colloid
stabil
polyplex
differ
physicochem
properti
plasmid
dna
sirna
approach
found
less
success
deliv
sirna
stiffer
structur
sirna
result
weaker
interact
polyc
consequ
polyplex
less
effici
protect
sirna
nucleas
increas
amount
polyc
may
offer
better
protect
might
contribut
toxic
altern
way
deliv
sirna
use
polym
prepar
polymer
nanoparticl
usual
solid
nanoparticl
made
hydrophob
polym
poli
llactidecoglycolid
plga
sirna
either
dispers
throughout
polym
matrix
surround
polymer
shell
polymer
nanoparticl
could
offer
better
protect
sirna
load
effici
main
challeng
deliveri
method
synthet
polym
pei
commonli
use
sirna
deliveri
due
high
intracellular
deliveri
effici
accord
proton
spong
hypothesi
mention
earlier
section
high
buffer
capac
pei
insid
acid
endosom
lead
swell
ruptur
endosom
therebi
promot
endosom
escap
pei
consid
gold
standard
vitro
gene
deliveri
transfect
effici
depend
molecular
weight
degre
branch
merkel
et
al
investig
use
pei
peipeg
polyplex
sirna
deliveri
lung
polyplex
contain
sirna
target
egfp
administ
actinegfp
express
mice
intratrach
instil
result
show
peipeg
system
display
better
deliveri
effici
knockdown
efgp
express
lung
tissu
howev
peipeg
polyplex
also
produc
moder
proinflammatori
effect
level
elev
pei
also
associ
problem
rel
high
toxic
lack
biodegrad
tackl
problem
xu
et
al
develop
new
degrad
pei
deriv
poli
ester
amin
altpeg
copolym
vivo
sirna
deliveri
previou
studi
confirm
biodegrad
low
toxic
polym
vivo
pulmonari
deliveri
polyplex
contain
sirna
target
aerosol
administ
mous
model
lung
cancer
noseonli
inhal
system
lung
cancer
progress
treat
mice
significantli
suppress
without
show
signific
sign
toxic
facilit
rapid
develop
pei
deriv
sirna
deliveri
thoma
et
al
employ
high
throughput
synthesi
screen
method
creat
combinatori
librari
biodegrad
pei
deriv
identifi
novel
vector
gene
deliveri
studi
focus
dna
deliveri
intraven
inject
mice
techniqu
could
easili
adapt
investig
pulmonari
sirna
deliveri
chitosan
attract
much
attent
potenti
vector
sirna
deliveri
due
natur
biocompat
biodegrad
low
toxic
natur
addit
mucoadhes
mucosa
permeat
properti
chitosan
make
particularli
favor
pulmonari
deliveri
unfortun
show
moder
vitro
vivo
transfect
effici
possibl
due
rel
weak
abil
promot
endosom
escap
chitosanbas
formul
sirna
deliveri
thoroughli
review
mao
et
al
recent
feasibl
use
chitosan
deliv
sirna
lung
demonstr
howard
et
al
chitosansirna
nanoparticl
prepar
addit
small
volum
sirna
chitosan
stock
solut
sodium
acet
buffer
nanoparticl
administ
intranas
egfpexpress
transgen
mice
number
egfp
express
epitheli
cell
bronchiol
reduc
compar
untreat
control
compar
mismatch
control
stabil
system
increas
molecular
weight
degre
deacetyl
recent
studi
conduct
group
describ
aerosol
chitosansirna
nanoparticl
intratrach
administr
attempt
improv
lung
deposit
mice
aerosol
gener
nebul
cathet
insert
noninvas
anim
vocal
cord
deliveri
rout
compar
intranas
rout
expect
result
confirm
aerosol
formul
improv
lung
deposit
sirna
dosag
egfp
express
transgen
mice
model
reduc
howev
author
also
point
cathet
insert
ensur
suffici
deliveri
effect
size
lung
deposit
investig
size
aerosol
droplet
gener
studi
around
suitabl
inhal
formul
critic
reduc
droplet
diamet
rang
allow
optim
lung
deposit
human
follow
inhal
enhanc
sirna
deliveri
effici
chitosan
kata
et
al
describ
ionic
gelat
method
use
sodium
tripolyphosph
produc
sirna
nanoparticl
compar
electrostat
complex
chitosansirna
nanoparticl
produc
ionic
gelat
method
show
better
vitro
gene
silenc
effect
due
better
stabil
higher
load
effici
would
interest
assess
vivo
perform
system
pulmonari
deliveri
plga
biodegrad
biocompat
polym
investig
provid
control
releas
therapeut
macromolecul
peptid
protein
plasmid
dna
versatil
plga
allow
chemic
modif
mani
deriv
plga
tailor
properti
design
fit
deliveri
purpos
unlik
polyc
plga
form
polyplex
nucleic
acid
instead
nucleic
acid
encapsul
plga
nanoparticl
manipul
degrad
rate
plga
sustain
releas
encapsul
nucleic
acid
could
achiev
design
inhal
formul
particl
size
extrem
import
doubl
emulsionsolv
evapor
convent
use
prepar
plga
nanoparticl
dri
particl
collect
lyophil
howev
larg
specif
surfac
area
particl
often
lead
aggreg
ice
format
lyophil
process
also
facilit
aggreg
result
particl
prepar
method
desir
inhal
formul
larg
particl
size
like
impact
oropharynx
area
takashima
et
al
demonstr
aggreg
plga
particl
contain
plasmid
dna
could
effect
minim
without
loss
vitro
transfect
effici
use
spraydri
techniqu
method
soon
adapt
jensen
et
al
demonstr
product
sirna
contain
plga
nanoparticl
spraydri
control
size
distribut
intend
inhal
plga
nanoparticl
cospraydri
carbohydr
excipi
lactos
trehalos
mannitol
protect
sirna
contain
nanoparticl
shear
forc
rais
temperatur
process
spraydri
ensur
particl
size
suitabl
inhal
physicochem
properti
powder
yield
formul
could
optim
vari
amount
excipi
nanoparticl
excipi
ratio
studi
show
integr
biolog
activ
sirna
preserv
spraydri
process
potenti
techniqu
gener
inhal
sirna
formul
confirm
investig
lung
deposit
vivo
gene
silenc
effici
sinc
discoveri
tat
protein
respons
cellular
uptak
viru
varieti
cellpenetr
peptid
cpp
deriv
synthes
cpp
frequent
employ
facilit
transport
therapeut
macromolecul
cell
strategi
extend
deliveri
sirna
cpp
deriv
investig
sirna
deliveri
includ
tat
penetratin
transportan
mpg
cadi
peptid
either
coval
attach
sirna
disulphid
bond
format
bind
sirna
electrostat
interact
form
complex
noncoval
manner
due
sequenc
divers
differ
cpp
mechan
action
also
expect
vari
peptid
improv
cellular
deliveri
effici
transport
cargo
across
biolog
membran
wherea
other
promot
endosom
escap
prevent
lysosom
degrad
howev
exact
mechan
peptid
still
controversi
activ
differ
cpp
extens
review
although
varieti
cpp
investig
sirna
deliveri
studi
report
use
vivo
pulmonari
deliveri
date
one
group
describ
use
cpp
vivo
deliveri
sirna
use
sirna
target
map
kinas
moscho
et
al
compar
gene
silenc
effect
nake
sirna
tatsirna
conjug
penetratinsirna
conjug
vitro
vivo
peptid
conjug
sirna
disulfid
linkag
sirna
conjug
nake
sirna
show
small
signific
reduct
map
kinas
express
mrna
level
mous
fibroblast
cell
line
interestingli
system
administr
intratrach
mous
model
nake
sirna
abl
produc
knockdown
map
kinas
lung
anim
despit
absenc
knockdown
effect
vitro
although
moder
gene
knockdown
observ
tatand
penetratinsirna
conjug
system
tat
penetratin
peptid
alon
also
produc
similar
knockdown
level
suggest
cpp
could
modul
map
kinas
express
gene
knockdown
effect
produc
sirna
furthermor
penetratinsirna
conjug
found
induc
vivo
innat
immun
respons
nake
sirna
tatsirna
conjug
penetratin
tat
alon
understand
mechan
cpp
activ
crucial
determin
applic
sirna
deliveri
addit
suggest
coval
attach
cpp
sirna
may
neg
effect
cellular
deliveri
biolog
activ
peptid
may
alter
chemic
modif
noncoval
complex
method
provid
altern
strategi
effect
lung
deliveri
anim
model
remain
seen
work
need
done
area
develop
effect
peptidebas
sirna
vector
system
vivo
pulmonari
deliveri
sinc
discoveri
sirna
therapeut
potenti
rapidli
recogn
mani
studi
carri
past
year
deliv
sirna
lung
treatment
variou
lung
diseas
howev
major
investig
focu
design
sirna
molecul
target
specif
diseas
instead
look
deliveri
perspect
order
make
sirna
therapi
practic
treat
human
lung
diseas
believ
inhal
rout
especi
dri
powder
form
best
choic
unfortun
literatur
describ
sirna
formul
specif
design
inhal
clinic
use
recent
jensen
et
al
report
spraydri
method
produc
plga
base
sirna
nanoparticl
physiochem
properti
intend
inhal
reach
stage
vivo
studi
yet
major
challeng
pulmonari
deliveri
sirna
includ
obviou
correl
vitro
vivo
studi
eg
nake
sirna
fail
show
gene
silenc
effect
vitro
mani
studi
vivo
studi
often
prove
otherwis
ii
hard
translat
inform
anim
especi
rodent
frequent
use
model
human
anatomi
physiolog
respiratori
tract
anim
human
distinct
iii
administr
rout
use
anim
studi
suitabl
human
use
extrem
difficult
evalu
deliveri
effici
formul
enter
clinic
studi
sinc
mani
studi
success
prove
therapeut
effici
sirna
variou
lung
diseas
final
hurdl
need
overcom
develop
inhal
stabl
sirna
formul
human
use
practic
way
sirna
therapeut
lung
diseas
becom
avail
clinic
